Beginning Oct. 1, AstraZeneca will tighten its 340B contract pharmacy restrictions to require claims data on 340B utilization at contract [...] …
Articles by : Bella Czajkowski, National Correspondent
The 340B program has outgrown patient demands and requires additional restrictions and oversight, according to a new report from a [...] …
Specialty and community pharmacies play an essential role in the 340B program and must be protected against interference by drug [...] …
November will bring an epic battle for both the U.S. presidency and control in Congress, both of which could have [...] …
Johnson & Johnson (J&J) has ended its contract pharmacy restrictions for covered entities in Arkansas, making the New Jersey-based pharmaceutical [...] …
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...] …
Six national hospital associations recently urged the Supreme Court to correct what they called the Department of Health and Human [...] …
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...] …
The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...] …
The Health Resources and Services Administration (HRSA) held a webinar yesterday to guide hospitals through their annual 340B recertification period, [...] …